Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study.
The renal, metabolic and antihypertensive effects of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind crossover trial in 22 patients with newly discovered essential hypertension. The glomerular filtration rate and renal vascular resistance were unaltered: renal blood flow was slightly decreased by V. Serum Ca2+ increased and Na+ excretion declined after V. Serum lipids, glucose, and erythrocyte electrolytes were unchanged. Blood pressure (BP) was lower with E after half the maximum dosage compared with V, but similar BP reductions were obtained after 2 months with the maximum dosage.
Fagher
B
B
Department of Medicine, Lund University Hospital, Sweden.
Henningsen
N
N
Hulthén
L
L
Katzman
P
P
Thulin
T
T
D000328:Adult; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000097:blood / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012083:Renin / Q000097:blood / Q000187:drug effects*; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D000804:Angiotensin II; D000450:Aldosterone; D004656:Enalapril; D014700:Verapamil; D012083:Renin